Cancer Survivorship Care Still Stalls at the Treatment Boundary
Two decades after survivorship care emerged as a formal priority, the transition from active cancer treatment to long-term follow-up still looks unfinished. A Journal of Clinical Oncology commentary by Michael Jefford, Raymond Javan Chan, Ines Vaz-Luis, Lonneke van de Poll-Franse, Wendy W.T. Lam, Carolyn Taylor, Nicole L. Stout, and Larissa Nekhlyudov returns to a problem oncology has discussed for years but never fully solved: what happens to patients after the last infusion, last operation, or last radiation fraction when the disease may be controlled but the consequences of treatment are only beginning.
The title alone captures the central tension. “Lost in transition” is not a metaphor for a minor administrative lapse; it describes a clinical gap that can shape symptom burden, surveillance quality, functional recovery, psychological health, and the risk that late effects will go unrecognized until they are harder to treat. Cancer care often excels at defining the start of treatment and the acute response window. It is far less consistent when the goal becomes restoring health after therapy has ended.
Survivorship care sits at the intersection of oncology, primary care, rehabilitation, psychosocial support, and chronic disease management. Patients may leave the oncology clinic with very different needs: one may require endocrine therapy adherence support, another may need surveillance for recurrence, a third may be living with neuropathy, fatigue, lymphedema, sexual dysfunction, cognitive complaints, or cardiometabolic risk amplified by therapy. A single follow-up schedule rarely fits all of these realities. The biological insult of treatment may be over, but its downstream effects often are not.
Why Transition Fails in Real Clinics
The hard part is not identifying survivorship as a concept. The hard part is building a durable handoff that actually works.
In practice, transition fails when responsibility is unclear. Oncology teams may assume primary care will manage general health maintenance, while primary care clinicians may hesitate to take ownership of cancer-specific surveillance or late-effect assessment. The result is predictable fragmentation: duplicate testing in some patients, missed monitoring in others, and a survivor who is forced to navigate the gap between systems. A care plan can exist on paper and still fail at the bedside if no one is accountable for the next decision.
The issue is also structural. Survivorship care requires time, specialized knowledge, communication, and reimbursement pathways that do not always align with the pace of busy oncology practice. Many treatment centers are designed to intensify care during diagnosis and therapy, then taper off once the active phase ends. Yet the clinical needs of survivors often increase after treatment ends, when fatigue persists, anxiety peaks, and late toxicities emerge. The transition point can be deceptively quiet, which is exactly why patients are vulnerable there.
Late Effects Demand More Than Reassurance
Cancer survivorship is not just about recurrence surveillance. It includes the lifelong management of treatment-related harm and the prevention of new comorbidity. Radiation, cytotoxic therapy, endocrine treatment, surgery, and immunotherapy can all leave lasting functional fingerprints. Some effects are visible and immediate; others unfold slowly, affecting cardiovascular health, bone health, fertility, cognition, sleep, work capacity, and quality of life. When these domains are not systematically assessed, patients may normalize symptoms that should trigger intervention.
Rehabilitation and supportive care belong inside survivorship rather than beside it. Lymphedema services, physical therapy, occupational therapy, nutrition counseling, pain management, mental health support, and sexual health care are not ancillary luxuries. They are part of restoring function after cancer therapy has altered normal physiology. A survivorship model that focuses only on scans and recurrence misses the everyday burdens that determine whether a patient can return to work, exercise, parent, or simply feel well enough to move through the day.
Shared Care Needs Clear Ownership
The most durable survivorship models usually rely on shared care, but shared care only works when roles are explicit. Patients need to know which clinician is tracking cancer-specific follow-up, which clinician is managing general preventive care, and where to go when a new symptom appears. Without that clarity, survivorship becomes an open loop. The patient carries the burden of coordination, and the system quietly shifts responsibility downward.
Care plans can help, but only if they are usable, updated, and connected to actual clinical decisions. A document that lists risks without naming the clinician responsible for each domain may satisfy an administrative requirement while leaving the patient unchanged. Survivorship care succeeds when follow-up is actionable: symptom review, surveillance intervals, vaccination, cardiometabolic prevention, rehabilitation referral, and psychosocial screening all need a place in routine practice.
The commentary’s very framing suggests a sobering reality after 20 years of discussion. Survivorship care has not failed because the need is unclear. It has struggled because oncology systems are still better at initiating treatment than integrating recovery.
What the Next Phase Requires
A credible survivorship model has to do more than remind clinicians that late effects exist. It has to distribute responsibility across the care team, recognize heterogeneity among survivors, and treat recovery as a clinical phase with its own workflows and accountability. That means adapting follow-up to risk, not applying a generic template to every patient who crosses the treatment threshold.
It also means acknowledging that survivorship is not a finish line. For many patients, it is the beginning of a new form of chronic care, one shaped by prior treatment exposure and by the emotional weight of living after cancer. The unanswered problem is not whether survivorship matters; it is whether health systems will finally build the coordination infrastructure needed to keep patients from being lost when the treatment room door closes.